Silodosin

Silodosin capsule, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see CLINICAL STUDIES (14)] . Silodosin capsule is not indicated for the treatment of hypertension. Silodosin capsule, an alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

Silodosin capsule is not indicated for the treatment of hypertension. (1)

Severe renal impairment (CCr <30 mL/min) Severe hepatic impairment (Child-Pugh score ≥10) Concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) [see DRUG INTERACTIONS (7.1)] Patients with a history of hypersensitivity to silodosin or any of the ingredients of silodosin capsules [see ADVERSE REACTIONS (6.2) and DESCRIPTION (11)] Patients with severe renal impairment [Creatinine Clearance (CCr <30 mL/min)].

(4) Patients with severe hepatic impairment (Child-Pugh score ≥ 10). (4) Concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir). (4) Patients with a history of hypersensitivity to silodosin or any of the ingredients of silodosin capsules. (4)

Postural hypotension, with or without symptoms (e.g., dizziness), may develop when beginning silodosin capsules treatment. (5.1) In patients with moderate renal impairment, silodosin capsules dose should be reduced to 4 mg once daily. (5.2) Silodosin capsules should not be used in combination with other alpha-blockers. (5.5) Examine patients thought to have BPH prior to starting therapy with silodosin capsules to rule out the presence of carcinoma of the prostate.

(5.6) Inform patients planning cataract surgery to notify their ophthalmologist that they are taking silodosin capsules because of the possibility of Intraoperative Floppy Iris Syndrome (IFIS). (5.7)

5.1Orthostatic Effects

Postural hypotension, with or without symptoms (e.g., dizziness) may develop when beginning silodosin capsules treatment. As with other alpha-blockers, there is potential for syncope. Patients should be cautioned about driving, operating machinery, or performing hazardous tasks when initiating therapy [see ADVERSE REACTIONS (6), USE IN SPECIFIC POPULATIONS (8.5), CLINICAL PHARMACOLOGY (12.2), and PATIENT COUNSELING INFORMATION (17)].